Drug Regulation and Oversight, from Local to Global

被引:1
作者
Babyar, Julie [1 ]
机构
[1] 415 Herondo St,Apt 332, Hermosa Beach, CA 90254 USA
关键词
Drug regulation; Regulatory medicine; Drug approval; International drug harmonization; Global medicine regulation; APPROVAL;
D O I
10.1007/s12247-017-9280-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this perspective piece is to address the potential for drug and medical product innovation through sound regulation and strengthened international harmonization. Current literature, recommendations and guidelines in regulatory agencies assisted in this perspective review. Multiple guidelines and recommendations provide for strategic planning and process improvement capabilities at local, national and international levels. Seeking best practice starts with identifying and improving individual nation drug regulatory bodies, including the US Food and Drug Administration (FDA). Inefficiency causes and process improvement solutions have been suggested and outlined in strategic plans at the FDA as well as with multiple stakeholder organizations and public-private partnerships. Cohesively, these groups should be tasked with formal, consistent updates on improvement as well as ongoing supportive research and evaluation of the changes implemented. Simultaneously, the international community has a tremendous opportunity to act on best practice for drug and medical product innovation by aligning sound and consistent approach to regulation.
引用
收藏
页码:185 / 187
页数:3
相关论文
共 50 条
  • [31] Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020
    Choi, Hyeyoung
    Lee, Hyesung
    Park, Bojung
    Kim, Chorong
    Lee, Jaehyun
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 552 - 560
  • [32] Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020
    Hyeyoung Choi
    Hyesung Lee
    Bojung Park
    Chorong Kim
    Jaehyun Lee
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 552 - 560
  • [33] FDA's decisions in oncology drug product approvals from 2006 to 2016
    Hyogo, Atsushi
    Kaneko, Masayuki
    Narukawa, Mamoru
    HEALTH POLICY AND TECHNOLOGY, 2018, 7 (04) : 341 - 346
  • [34] Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels
    Yeh, James S.
    Sarpatwari, Ameet
    Kesselheim, Aaron S.
    DRUG SAFETY, 2016, 39 (08) : 709 - 714
  • [35] Connecting pre-marketing clinical research and medical practice - Opinion-based study of core issues and possible changes in drug regulation
    Wieringa, NF
    Peschar, JL
    Denig, P
    de Graeff, PA
    Vos, R
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2003, 19 (01) : 202 - 219
  • [37] Surrogate endpoint evaluation using data from one large global randomized controlled trial
    Geybels, Milan
    Wolthers, Benjamin Ole
    Kreiner, Frederik Flindt
    Rasmussen, Soren
    Bauer, Robert
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2021, 21 (01)
  • [38] Harmonizing Standards and Incentives in Medical Device Regulation: Lessons Learned from the Parallel Review Pathway
    Holtzman, Jessica N.
    Kramer, Daniel B.
    JOURNAL OF LAW MEDICINE & ETHICS, 2018, 46 (04) : 1034 - 1039
  • [39] Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study
    Maeda, Hideki
    Hara, Asuka
    Ofuchi, Momoka
    Shingai, Riko
    Misumi, Toshihiro
    Murai, Yuna
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (12): : 2665 - 2674
  • [40] Lessons from Canada's notice of compliance with conditions policy for the life-cycle regulation of drugs
    McPhail, Melanie
    Zhang, Howard
    Bhimani, Zohra
    Bubela, Tania
    JOURNAL OF LAW AND THE BIOSCIENCES, 2023, 10 (01):